Development of the MANTAP score for predicting one-year mortality in intermediate-stage hepatocellular carcinoma patients undergoing transarterial chemoembolization

Key Points

• One-year mortality prediction can be improved with the MANTAP score, specifically tailored for intermediate-stage patients.
• Key evidence shows that patients undergoing transarterial chemoembolization can be accurately assessed using this new scoring method.
• This analysis utilized data from patients diagnosed with intermediate-stage hepatocellular carcinoma, focusing on their mortality risks.
• Introducing the MANTAP score may enhance clinical decision-making, although validation in larger cohorts is needed.